Nearly half of all Alzheimer's disease cases may be preventable, yet the United States has been remarkably slow to build systematic risk-reduction programs into routine care. The central question has been whether this gap reflects skepticism about prevention strategies or something more structural — and this survey of over 2,000 participants begins to answer it.
Among 2,054 respondents drawn from both healthcare consumers and providers, lifestyle interventions consistently outranked pharmaceutical approaches in desirability. Consumer respondents rated lifestyle interventions at a mean Likert score of 4.5 versus 3.5 for pharmaceutical options — a statistically significant difference. Providers mirrored this pattern, rating lifestyle interventions at 3.86 compared to 2.81 for pharmaceuticals. Consumers expressed the strongest enthusiasm for personalized risk-reduction plans, with a mean score of 4.82. Providers, meanwhile, signaled readiness to act — specifically indicating interest in medical education resources, referral networks, and blood biomarker testing — but flagged the absence of structured guidance as a key barrier.
This finding reframes the prevention gap as a systems and infrastructure problem rather than an attitude problem. The assumption that clinicians lack motivation or patients lack interest appears to be unfounded; instead, neither group has adequate scaffolding to act on their existing willingness. This is meaningful context for the broader Alzheimer's prevention landscape, where modifiable risk factor research has accelerated — particularly around metabolic health, sleep, cardiovascular fitness, and hearing loss — but translation into clinical workflows remains underdeveloped. The survey's demographic skew toward White, female respondents aged 51–79 limits generalizability across the populations at highest dementia risk. As an observational, self-selected online survey, it captures stated preferences rather than behavior. Still, the convergence of patient and provider attitudes toward lifestyle-first, personalized care points to a clear opportunity: structured preventive neurology frameworks, supported by continuing medical education and biomarker tools, could mobilize a workforce that is already motivated.